Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.25.

ESPR has been the subject of a number of research analyst reports. The Goldman Sachs Group dropped their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Friday, April 25th. JMP Securities reaffirmed a "market outperform" rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th.

Institutional Trading of Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. Jones Financial Companies Lllp acquired a new position in Esperion Therapeutics during the first quarter worth about $278,000. Graham Capital Management L.P. grew its stake in shares of Esperion Therapeutics by 153.5% in the 1st quarter. Graham Capital Management L.P. now owns 487,735 shares of the biopharmaceutical company's stock worth $702,000 after purchasing an additional 295,320 shares during the last quarter. State of Wyoming boosted its holdings in Esperion Therapeutics by 93.8% during the first quarter. State of Wyoming now owns 89,936 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 43,526 shares in the last quarter. CW Advisors LLC acquired a new position in shares of Esperion Therapeutics in the 1st quarter worth $74,000. Finally, Summit Financial LLC raised its position in shares of Esperion Therapeutics by 40.1% during the first quarter. Summit Financial LLC now owns 65,194 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 18,666 shares during the period. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Stock Down 0.8%

Shares of ESPR traded down $0.01 on Wednesday, reaching $1.21. The stock had a trading volume of 2,928,448 shares, compared to its average volume of 5,331,574. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $3.94. The firm has a market capitalization of $239.82 million, a PE ratio of -1.89 and a beta of 0.67. The firm has a 50-day moving average of $0.95 and a 200 day moving average of $1.68.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million. On average, sell-side analysts anticipate that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.